The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
FDA grants orphan drug status to an investigational NK cell-based therapy for the treatment of multiple myeloma
On November 4, 2020, the U.S. Food and Drug Administration (FDA) granted orphan drug designation to an investigational natural killer (NK) cell-based therapy (CellProtect) for the treatment of newly diagnosed multiple myeloma.1
The orphan drug designation of this autologous NK cell-based product was based on the results from the first-in-human phase I/II ACP-001 clinical trial (NCT04558853).2 This open-label, single-arm trial evaluated the safety and efficacy of the investigational NK cell product in 12 patients as consolidation, following high dose therapy plus autologous stem cell transplantation (auto-SCT). The product was infused in a triple escalating dose:2
- 1st infusion: 5 × 106 cells/kg
- 2nd infusion: 50 × 106 cells/kg
- 3rd infusion: 100 × 106 cells/kg
The product showed a good safety profile, with no severe adverse events reported, and promising efficacy data: four out of six patients with measurable disease after auto-SCT improved their depth of response after NK cell infusion.2
A phase II study will evaluate this autologous NK cell-based product combined with isatuximab (an anti-CD38 monoclonal antibody) as maintenance after auto-SCT. This clinical trial is planned to begin recruitment soon (NCT04558931).2
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content